Hexylitaconic acid

Potential MoA: Hexylitaconic acid exhibits antitumor activity by inhibiting p53-MDM2 interaction. The exact mechanism remains unknown, but it may involve binding of the vinylidene group to the Cys77 residue of MDM2. Possible Anti-Cancer-Application: The potential therapeutic applications of this compound in cancer treatment have been explored. Studies have identified it as an inhibitor of the p53-HDM2 interaction, a crucial pathway in cancer biology. Possible Obesity application: In the field of metabolomics, this compound has been identified in studies related to diabetes. It was detected in a multiplatform metabolomics study involving patients with diabetes, highlighting its potential role in metabolic pathways associated with the disease. This indicates its importance in understanding metabolic disturbances in diabetes.